Healwell AI Inc.

DB:6H90 Stock Report

Market Cap: €176.6m

Healwell AI Valuation

Is 6H90 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6H90 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6H90's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6H90's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6H90?

Key metric: As 6H90 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6H90. This is calculated by dividing 6H90's market cap by their current revenue.
What is 6H90's PS Ratio?
PS Ratio10.2x
SalesCA$25.69m
Market CapCA$261.13m

Price to Sales Ratio vs Peers

How does 6H90's PS Ratio compare to its peers?

The above table shows the PS ratio for 6H90 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
V3V VITA 34
0.9x3.1%€73.6m
SYAB SYNLAB
1x4.4%€2.5b
FRE Fresenius SE KGaA
0.8x3.6%€18.6b
MED MEDICLIN
0.2x0.7%€121.6m
6H90 Healwell AI
10.2x49.2%€261.1m

Price-To-Sales vs Peers: 6H90 is expensive based on its Price-To-Sales Ratio (10.2x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does 6H90's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.90m
No more companies available in this PS range
6H90 10.2xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6H90 is expensive based on its Price-To-Sales Ratio (10.2x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 6H90's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6H90 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.2x
Fair PS Ratio5.1x

Price-To-Sales vs Fair Ratio: 6H90 is expensive based on its Price-To-Sales Ratio (10.2x) compared to the estimated Fair Price-To-Sales Ratio (5.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6H90 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.10
€2.49
+126.4%
19.3%€3.44€1.72n/a8
Nov ’25€0.88
€2.42
+174.8%
18.7%€3.30€1.65n/a8
Oct ’25€1.01
€2.59
+158.1%
16.4%€3.32€1.99n/a5
Sep ’25€1.24
€2.59
+109.2%
16.4%€3.32€1.99n/a5
Aug ’25€1.45
€2.66
+83.5%
16.4%€3.40€2.04n/a5
Jul ’25€1.69
€2.66
+57.9%
16.4%€3.40€2.04n/a5
Jun ’25€1.25
€1.51
+20.8%
8.7%€1.69€1.32n/a4
May ’25€1.05
€0.91
-12.7%
12.8%€1.02€0.75n/a4
Apr ’25€0.66
€0.88
+35.1%
12.9%€1.03€0.76n/a3
Mar ’25€0.76
€0.88
+17.2%
12.9%€1.03€0.76n/a3
Feb ’25€0.50
€0.89
+78.9%
15.4%€1.03€0.75n/a2
Jan ’25€0.48
€0.89
+85.5%
15.4%€1.03€0.75n/a2
Dec ’24€0.68
€0.89
+31.1%
15.4%€1.02€0.75n/a2
Mar ’24€0.40
€0.87
+118.3%
16.7%€1.01€0.72€0.762
Feb ’24€0.45
€0.87
+93.1%
16.7%€1.01€0.72€0.502
Jan ’24€0.30
€0.87
+185.8%
16.7%€1.01€0.72€0.482
Dec ’23€0.36
€0.87
+141.3%
16.7%€1.01€0.72€0.682
Nov ’23€0.74
€1.38
+85.0%
16.7%€1.61€1.15€0.422

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%